Background: Although chemoradiotherapy with full-dose gemcitabine as a strategy for locally advanced pancreatic cancer was expected to optimize local tumor control and prevent distant metastasis, the volume of the radiation field is the critical factor related to toxicities. We are currently developing a novel therapeutic technique to conduct neoadjuvant treatments of intra-arterial chemoinfusion prior to chemoradiotherapy with the aim of tumor volume reduction.
Case Report: In two patients with locally invasive pancreatic cancer, the pancreatic blood supply was altered under angiographic guidance, and an intra-arterial catheter with a subcutaneous port was left in place for the administration of 5-fluorouracil (5-FU) 1,000 mg/m(2). After shrinkage of the tumor, chemoradiotherapy with gemcitabine 1,000 mg/m(2) was delivered. In both patients, the full-dose gemcitabine was administered concurrently with radiation therapy without severe complications. The patients responded to the treatment with survival times of 42 and 38 months.
Conclusion: Intra-arterial chemoinfusion followed by chemoradiation with full-dose systemic gemcitabine might prove to be a promising therapeutic approach for locally advanced pancreatic cancer. Large prospective Phase II trials of this combination regimen are warranted.
Download full-text PDF |
Source |
---|
Ann Oncol
February 2025
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address:
Background: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer.
Materials And Methods: We derived population data and death certificates for all cancers and major sites for the EU, France, Germany, Italy, Poland, Spain, and the UK since 1970, from the World Health Organization and United Nations databases. Estimates for 2025 were computed by linear regression on recent trends identified through Poisson joinpoint regression, considering the slope of the most recent trend segment.
J Genet Eng Biotechnol
March 2025
Karachi Medical and Dental College, Pakistan. Electronic address:
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%. Its late diagnosis and limited treatment options contribute to poor outcomes. Immunotherapy has had little success due to PDAC's dense and immunosuppressive tumor environment.
View Article and Find Full Text PDFKeio J Med
March 2025
Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.
Hereditary breast and ovarian cancer syndrome (HBOC) is traditionally associated with mutations in the BRCA1 and BRCA2 genes, predominantly impacting breast, ovarian, pancreatic, and prostate cancers. However, recent research suggests that these mutations may also predispose carriers to a broader spectrum of malignancies, including biliary tract, cervical, colorectal, endometrial, esophageal, and gastric cancers. This review presents findings from extensive datasets, including a significant study from a nationwide Japanese biobank that examined cancer risks in 63,828 patients and 37,086 controls.
View Article and Find Full Text PDFOccup Environ Med
March 2025
Research Directorate, Veterans Affairs Canada, Charlottetown, Prince Edward Island, Canada
Objectives: To describe rates of overall and type-specific primary cancers in Canadian Armed Forces (CAF) personnel and Veterans with a first enrolment in the CAF between 1976 and 2016, with comparisons to the Canadian general population (CGP).
Methods: This retrospective cohort study linked CAF administrative data to national cancer registries. Primary cancer diagnoses were ascertained from 1976 to 2017.
Int J Radiat Oncol Biol Phys
March 2025
Department of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan; Department of Oncology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Background: Randomized trials and meta-analyses have indicated longer survival with neoadjuvant than with adjuvant therapy in patients with resectable or borderline resectable (R/BR) pancreatic adenocarcinoma. Despite the efficacy of chemotherapy, the role of radiotherapy as an adjuvant or neoadjuvant treatment for patients with R/BR pancreatic adenocarcinoma remains unclear. In this systematic review and meta-analysis, we compared the benefits of additional chemoradiotherapy (CRT) to neoadjuvant chemotherapy (NAC) with NAC alone for R/BR pancreatic adenocarcinoma.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!